Phosphoproteomics Study Drives Phase I Trial Testing Pfizer ALK Inhibitor as Breast Cancer Therapy | GenomeWeb

By Adam Bonislawski

Researchers at the University of Texas MD Anderson Cancer Center and George Mason University presented data this week that suggests anaplastic lymphoma kinase, or ALK, inhibitors may be useful in the treatment of inflammatory breast cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.